IFPMA 2014 interview series ‘8th Asia Regulatory Conference’
Title: JPMA Welcome Message to the 8th Asia Regulatory Conference (ARC)
This short interview video is a prerecorded welcome message to the 8th Asia Regulatory Conference (ARC) posted online. Dr Inagaki talks about what the 2015 ARC conference in Chinese Taipei is all about. He also mentions the role played by the Asia Partnership Conference of Pharmaceutical Associations (APAC), a platform led by JPMA, in regulatory convergence. Dr Inagaki also explains why key players in the regulatory field in the region should not miss out on this event.
Dr Inagaki is the Staff Senior Executive Director, Global Planning and Administration, Astellas Pharma, and the chairperson of the Drug Evaluation Committee in the Japan Pharmaceutical Manufacturers Association (JPMA).
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
IFPMA-INTERFARMA-FIFARMA statement on the Rio de Janeiro Declaration of the G20 Health Ministers
The innovative pharmaceutical industry, represented by IFPMA, INTERFARMA and FIFARMA reiterates its commitment to the G20 health priorities, reaffirmed in the Rio de Janeiro Declaration.
Read moreWHO EMRO RC71: Regional flagship initiative 1: Expanding equitable access to medical products
On 14 October 2024 in Doha, Qatar, IFPMA delivered a statement at the 71st session of the WHO EMRO Regional Committee on the Regional flagship initiative 1: Expanding equitable access to medical products.
Read moreThe Value of Reference Agency Assessment Reports in Enabling Regulatory Reliance
Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...
Read more